Greece quarantines second camp after coronavirus case confirmed

Greece has quarantined two camps. (File/AFP)
Short Url
Updated 05 April 2020

Greece quarantines second camp after coronavirus case confirmed

  • The infected man has been transferred to a hospital in Athens
  • Tests on his contacts will continue as the public health agency tries to trace the route of the virus

ATHENS: Greece has quarantined a second migrant facility this week after a 53-year-old man tested positive for coronavirus, the migration ministry said on Sunday. Tha Afghan man, who was found to be infected, lives with his family at the Malakasa camp along with hundreds of other migrants and asylum seekers. He has been transferred to a hospital in Athens. Tests on his contacts will continue as the public health agency tries to trace the route of the virus.
On Thursday, authorities quarantined the Ritsona camp in central Greece after 20 asylum seekers tested positive for coronavirus. It was the first such facility in Greece to be hit since the outbreak of the disease.
The camp in Malakasa, 40km northeast of Athens, will be put into quarantine for two weeks, the ministry said, adding that police guarding the site would be reinforced.
A new separate closed-type facility started operating last month for migrants who arrived after March 1, the ministry said.


US to pay over $1bn for 100m doses of J&J’s potential COVID-19 vaccine

Updated 32 min ago

US to pay over $1bn for 100m doses of J&J’s potential COVID-19 vaccine

  • The latest contract equates to roughly $10 per vaccine dose produced by J&J
  • This is J&J’s first deal to supply its investigational vaccine to a country

WASHINGTON: The United States government will pay Johnson & Johnson over $1 billion for 100 million doses of its potential coronavirus vaccine, its latest such arrangement as the race to tame the pandemic intensifies, the drugmaker said on Wednesday.
It said it would deliver the vaccine to the Biomedical Advanced Research and Development Authority (BARDA) on a not-for-profit basis to be used after approval or emergency use authorization by the US Food and Drug Administration (FDA).
J&J has already received $1 billion in funding from the US government — BARDA agreed in March to provide that money for the company to build manufacturing capacity for more than 1 billion doses of the experimental vaccine.
The latest contract equates to roughly $10 per vaccine dose produced by J&J. Including the first $1 billion deal with the USgovernment, the price would be slightly higher than the $19.50 per dose that the United States is paying for the vaccine being developed by Pfizer Inc. and German biotech BioNTech SE.
The US government may also purchase an additional 200 million doses under a subsequent agreement. J&J did not disclose that deal’s value.
J&J plans to study a one- or two-dose regimen of the vaccine in parallel later this year. A single-shot regimen could allow more people to be vaccinated with the same number of doses and would sidestep issues around getting people to come back for their second dose.
This is J&J’s first deal to supply its investigational vaccine to a country. Talks are underway with the European Union, but no deal has yet been reached.
J&J’s investigational vaccine is currently being tested on healthy volunteers in the United States and Belgium in an early-stage study.
There are currently no approved vaccines for COVID-19. More than 20 are in clinical trials.